Borut Jerman

TL;DR: The results suggest that efficacy of antidepressants may be predicted by genetic markers other than traditional candidates, and genome-wide studies, if properly replicated, may be important steps in the elucidation of the genetic basis of pharmacological response.

TL;DR: Testing whether genetic information could inform the selection of the best drug for patients with depression, Rudolf Uher and colleagues searched for genetic variants that could predict clinically meaningful responses to two major groups of antidepressants.

TL;DR: The genetic liability to MDD or schizophrenia did not predict response to antidepressants, suggesting differences between the genetic component of depression and treatment response, and larger or more homogeneous studies will be necessary to obtain a polygenic predictor of antidepressant response.

TL;DR: In this paper, an integrative analysis from the Genome-Based Therapeutic Drugs for Depression (GENDEP) study using gene expression from mice to inform prioritization in a human pharmacogenetic study was performed.

TL;DR: Overall burden of CNVs is unlikely to contribute to personalising antidepressant treatment, and specific CNVs associated with antidepressant treatment require replication and further study to confirm their role in the therapeutic action of antidepressant.